Lupin

Update of acquisition of VISUfarma B.V., the Netherlands.

30 Dec, 2025 | 04:29pm • Source: BSE

Lupin signs Exclusive Licensing Agreement with Gan & Lee Pharmaceuticals for novel GLP-1 receptor agonist.

29 Dec, 2025 | 06:26pm • Source: BSE

Intimation of Closure of Trading Window

26 Dec, 2025 | 03:33pm • Source: BSE

Lupin Signs Exclusive Licensing Agreement with Neopharmed for Gastroenterology Brand Plasil in the Philippines and Brazil.

18 Dec, 2025 | 03:50pm • Source: BSE

Lupin Limited has informed the Exchange regarding a press release dated December 17, 2025, titled "Lupin Receives Positive CHMP Opinion for Biosimilar Ranibizumab

17 Dec, 2025 | 01:20pm • Source: NSE

Lupin Receives Positive CHMP Opinion for Biosimilar Ranibizumab.

17 Dec, 2025 | 11:53am • Source: BSE

Lupin Limited has informed the Exchange regarding a press release dated December 16, 2025, titled "Lupin Secures SBTi Validation for Emission Reduction Targets

16 Dec, 2025 | 10:07am • Source: NSE

Lupin Secures SBTi Validation for Emission Reduction Targets.

16 Dec, 2025 | 10:01am • Source: BSE

Lupin Limited has informed the Exchange regarding a press release dated December 12, 2025, titled "Lupin Manufacturing Solutions and PolyPeptide Announce Strategic Alliance to ScaleGlobal...

12 Dec, 2025 | 11:55am • Source: NSE

Lupin Manufacturing Solutions and PolyPeptide Announce Strategic Alliance to Scale Global Peptide Supply Chain.

12 Dec, 2025 | 11:47am • Source: BSE

Intimation regarding allotment of 36626 shares under ESOP.

10 Dec, 2025 | 04:13pm • Source: BSE

ESG Rating by NSE Sustainability Ratings & Analytics Limited.

09 Dec, 2025 | 06:01pm • Source: BSE

Lupin Receives Tentative Approval from U.S. FDA for Siponimod Tablets.

05 Dec, 2025 | 09:32am • Source: BSE

Lupin and Valorum Enter into an Exclusive Licensing Agreement for Biosimilar Armlupeg (Pegfilgrastim-unne) in the United States.

04 Dec, 2025 | 01:22pm • Source: BSE

Lupin Receives Approval from U.S. FDA for Biosimilar Armlupeg (Pegfilgrastim-unne).

01 Dec, 2025 | 07:44am • Source: BSE

Lupin Limited has informed the Exchange regarding a press release dated November 28, 2025, titled "Lupin Foundation Earns CRISIL s Highest VO 1A Rating for...

28 Nov, 2025 | 12:02pm • Source: NSE

Lupin Foundation Earns CRISIL''s Highest VO 1A Rating for Excellence in Social Responsibility.

28 Nov, 2025 | 11:42am • Source: BSE

U.S. FDA has conducted an inspection at Company''s manufacturing facility located at Goa, India.

21 Nov, 2025 | 10:47pm • Source: BSE

Lupin Limited has informed the Exchange regarding a press release dated November 14, 2025, titled "Lupin Launches Risperidone Long-Acting Injectable with 180-day CGT exclusivity in...

14 Nov, 2025 | 09:01am • Source: NSE

Lupin Launches Risperidone Long-Acting Injectable with 180-day CGT Exclusivity in the U.S., the first product from its proprietary Long-Acting Injectable platform PrecisionSphere.

14 Nov, 2025 | 07:22am • Source: BSE